Cargando…
Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial
BACKGROUND: Two large randomised trials of patients with well-differentiated thyroid cancer reported in 2012 (HiLo and ESTIMABL1) found similar post-ablation success rates at 6–9 months between a low administered radioactive iodine ((131)I) dose (1·1 GBq) and the standard high dose (3·7 GBq). Howeve...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Lancet, Diabetes & Endocrinology
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299255/ https://www.ncbi.nlm.nih.gov/pubmed/30501974 http://dx.doi.org/10.1016/S2213-8587(18)30306-1 |